(AGENPARL) - Roma, 3 Dicembre 2024 - (AGENPARL) – mar 03 dicembre 2024 The trial will be conducted in patients with pre-existing anti-AAV antibodies
which limit use of gene therapy treatment
Lund, Sweden and Evry, France 3 December 2024. Hansa Biopharma, “Hansa” (Nasdaq
Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy research
and development for rare genetic diseases, today announced initiation of GNT-018
-IDES, a Phase 2 trial in patients with Crigler-Najjar syndrome with pre
-existing antibodies against adeno-associated virus (AAV) vectors. The trial
will evaluate the efficacy and safety of a single intravenous administration of
Genethon’s gene therapy GNT-0003 following pre-treatment with imlifidase,
Hansa’s first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy,
in patients with severe Crigler-Najjar syndrome and pre-formed antibodies to AAV
serotype 8 (AAV8).
Søren Tulstrup, President and CEO, Hansa Biopharma said, “We know that anti-AAV
antibodies prevent up to 1 in 3 people from benefitting from gene therapies
using AAV-vectors.[1-4] That’s why our collaboration with Genethon and the
initiation of the Phase 2 clinical trial in Crigler-Najjar syndrome is so
important. This collaboration with Genethon is the second of our three
partnerships with leading gene therapy companies to have reached the clinical
stage, marking an important milestone in our efforts to enable a much larger
group of patients to benefit from potentially lifesaving gene therapies.”
Antibodies against AAV vectors remain a major challenge, as their presence in
patients excludes them from entering clinical studies with potentially curative
gene therapy treatments and from access to currently marketed and future gene
therapies.
Frédéric Revah, CEO, Genethon added: “This new clinical trial reflects
Genethon’s commitment in pursuing innovative strategies to ensure and broaden
access to gene therapies for patients suffering from rare diseases. Patients
with pre-existing neutralizing antibodies against AAV vectors cannot today
benefit from gene therapy. The initiation of this clinical trial and the
collaboration with Hansa Biopharma is a crucial step for Genethon and highlights
several years of pioneering research to understand and control the immune
response to AAV in order to make gene therapy more effective and to increase the
number of patients able to access it.”
GNT-018-IDES, sponsored by Genethon, is a single arm Phase 2 trial with a total
of three patients aged ?18 years with Crigler-Najjar syndrome and pre-formed
anti-AVV8 antibodies and requiring phototherapy. Once screened, patients will
undergo a three-month observational period before being dosed with imlifidase
followed by GNT-0003. Genethon and Hansa expect to communicate data from the
trial in 2025.
GNT-0003 is currently being evaluated in a pivotal clinical trial following the
positive results of the phase 1-2 dose escalation study showing safety and
efficacy of GNT-0003, and was granted PRIME priority drug status from the EMA.
If successful, GNT-0003 would be the first gene therapy treatment for Crigler
-Najjar syndrome.
— ENDS —
Contacts for more information:
HANSA BIOPHARMA
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
GENETHON
Stéphanie Bardon
Notes to editors
About imlifidase
Imlifidase is a unique antibody-cleaving enzyme originating from Streptococcus
pyogenes that specifically targets IgG and inhibits IgG-mediated immune
response.[5] It has a rapid onset of action, cleaving IgG-antibodies and
inhibiting their activity within hours after administration. Imlifidase has
conditional marketing approval in Europe and is marketed under the trade name
IDEFIRIX[®] for the desensitization treatment of highly sensitized adult kidney
transplant patients with a positive crossmatch against an available deceased
donor.[5]
About Crigler-Najjar syndrome
Crigler-Najjar syndrome is a rare genetic liver disease characterized by
abnormally high levels of bilirubin in the blood (hyperbilirubinemia), which
leads to irreversible neurological damage manifested as muscle weakness,
lethargy, deafness, mental retardation, and eye movement paralysis. This
accumulation of bilirubin is caused by a deficiency of the UGT1A1 enzyme,
responsible for transforming bilirubin into a substance that can be eliminated
by the body. It can result in significant neurological damage and death if not
treated quickly. At present, patients must undergo phototherapy for up to 12
hours a day to keep their bilirubin levels below the toxicity threshold. Crigler
-Najjar syndrome is an ultra-rare disease affecting less than one case per one
million people per year.[6]
About imlifidase and gene therapy
Imlifidase is currently being evaluated as a pre-treatment to gene therapy in
areas of high unmet need. Many gene therapies are based on the use of Adeno
Associated Viruses (AAV) vectors.[1-4,7] In some patients the immune system
carries antibodies that counteract the gene therapy treatment preventing its
success.[ 1-4,8-10] Pre-treatment with imlifidase prior to AAV-based gene
therapy treatment has the potential to inactivate antibodies and thereby enable
gene therapy in patients with pre-existing antibodies to AAV-based gene
therapies.[9] Currently, it is estimated that anti-AAV antibodies on average
prevent 1 in 3 people from benefiting from gene therapy treatments.[1-4,8]
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. Hansa Biopharma has
developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme
therapy, which has been shown to enable kidney transplantation in highly
sensitized patients. Hansa Biopharma has a rich and expanding research and
development program based on the Company’s proprietary IgG-cleaving enzyme
technology platform, to address serious unmet medical needs in transplantation,
autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund,
Sweden, and has operations in Europe and the U.S. The company is listed on
Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com
and follow us on LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
About Genethon
A pioneer in the discovery and development of gene therapies for rare diseases,
Généthon is a non-profit organization created by the AFM-Téléthon. The first
gene therapy to treat spinal muscular atrophy, incorporating technologies
developed at Genethon, is marketed worldwide. With over 200 scientists and
professionals, Genethon pursues its goal of developing innovative therapies that
change the lives of patients suffering from rare genetic diseases. Thirteen
products from Genethon’s R&D or collaborations are in clinical trials for
diseases of the liver, blood, immune system, muscles and eyes. A further seven
products could enter clinical trials in the next five years. To find out more
www.genethon.com
©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
References
1. Boutin S, et al. Prevalence of serum IgG and neutralizing factors against
adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy
population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010
2. Calcedo R, Wilson JM. Humoral Immune Response to AAV. Front Immunol. 2013
3. Veron P, Leborgne C, Monteilhet V, Boutin S, Martin S, Moullier P, Masurier
C. Humoral and cellular capsid-specific immune responses to adeno-associated
virus type 1 in randomized healthy donors. J Immunol. 2012 Jun 15;188(12):6418
4. Kruzik A, et al. Prevalence of Anti-Adeno-Associated Virus Immune Responses
in International Cohorts of Healthy Donors. Mol Ther Methods Clin Dev. 2019 Jun
5. European Medicines Agency. Idefirix® summary of product characteristics.
Available at: https://www.ema.europa.eu/en/documents/product
-information/idefirix-epar-product-information_en.pdf.
6. https://www.genethon.com/our-pipeline/crigler-najjar-syndrome/. Last
accessed: 29 November 2024
7. Lundstrom K. Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
8. Falese L, et al. Strategy to detect pre-existing immunity to AAV gene
therapy. Gene Ther. 2017 Dec;24(12):768-778. doi: 10.1038/gt.2017.95. Epub 2017
9. Leborgne C, et al. IgG-cleaving endopeptidase enables in vivo gene therapy
in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020
Jul;26(7):1096-1101. doi: 10.1038/s41591-020-0911-7. Epub 2020 Jun 1. PMID:
10. Au H.K, et al. (2022) Gene Therapy Advances: A Meta-Analysis of AAV Usage in
Clinical Settings. Front. Med. 8:809118. doi: 10.3389/fmed.2021.809118
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3PXRrC22AfUVPKSsDjuFakFYdQKLyGL7H4JNaU7X3fVniDKC7ufibzTb4m9arqwQYqaHUJmYdHBq87CvYzXYKdBWj6EbxiUpZYFP6ZQ6UHjRNe.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3PXRrC22AfUVPKSsDjuFakFYdQKLyGL7H4JNaU7X3fVniDKC7ufibzTb4m9arqwQYqaHUJmYdHBq87CvYzXYKdBWj6EbxiUpZYFP6ZQ6UHjRNe.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content
Trending
- La Cina rafforza la sua influenza in Asia centrale: accordo strategico sul gas in Kazakistan e nuove intese economiche nella regione
- Rifondazione Comunista: ddl anti Palestina liberticida, campo largo si impegni a abrogarlo
- COMUNICATO STAMPA CONSIGLIO DEI MINISTRI N. 198 18/11/2026 PALAZZO CHIGI
- Riforma forense, Ostellari (Lega): impegno mantenuto, più garanzie per avvocati e cittadini
- FEMMINICIDIO: BILOTTI (M5S), A SALERNO 3 DONNE UCCISE IN POCHE ORE. NON SI SPOSTI FULCRO DA VIOLENZA
- BOSCAINI (FI) AL GOVERNO: “SIANO VERIFICATE LE COPERTURE FINANZIARIE DEL PROGETTO DI POTENZIAMENTO, CHE VA REALIZZATO ENTRO 6 ANNI, PRIMA DELLA GALLERIA DEL BRENNERO”
- MANOVRA: DOMANI CONFERENZA STAMPA FDI ALLA CAMERA SUGLI INTERVENTI PER L’AGRICOLTURA
- DL CORTEI. ZUCCONI (FDI): PLAUSO A EMENDAMENTO STOP SOCIAL UNDER 13. UNA BATTAGLIA DI CIVILTÀ
- DDL ANTISEMITISMO: ORSINI (FI), “IL DIRITTO DI ESSERE ANTISEMITI NON FA PARTE DELLA LIBERT?
- DDL ANTISEMITISMO: ORSINI (FI), “SCHLEIN INCOERENTE SULLA DEFINIZIONE IHRA